ClinicalTrials.gov

History of Changes for Study: NCT04170829
A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate (MERS-CoV) Vaccine ChAdOx1 MERS
Latest version (submitted November 24, 2019) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 November 18, 2019 None (earliest Version on record)
2 November 24, 2019 Recruitment Status, Contacts/Locations, Study Status and Study Identification
Comparison Format:

Scroll up to access the controls

Study NCT04170829
Submitted Date:  November 18, 2019 (v1)

Study Identification
Unique Protocol ID: CT18/004/R
Brief Title: A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate (MERS-CoV) Vaccine ChAdOx1 MERS
Official Title: A Phase Ib Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers
Secondary IDs: MERS002 [Other Grant/Funding Number: University of Oxford]
Study Status
Record Verification: November 2019
Overall Status: Not yet recruiting
Study Start: January 1, 2020
Primary Completion: September 1, 2020 [Anticipated]
Study Completion: January 1, 2021 [Anticipated]
First Submitted: November 14, 2019
First Submitted that
Met QC Criteria:
November 18, 2019
First Posted: November 20, 2019 [Actual]
Last Update Submitted that
Met QC Criteria:
November 18, 2019
Last Update Posted: November 20, 2019 [Actual]
Sponsor/Collaborators
Sponsor: King Abdullah International Medical Research Center
Responsible Party: Sponsor
Collaborators: University of Oxford
Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring:
Study Description
Brief Summary: A phase Ib study to determine the safety and immunogenicity of the candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers
Detailed Description:

This is an open-label, dose escalation phase 1b trial to assess the safety and immunogenicity of the candidate ChAdOx1 MERS vaccine in healthy Middle Eastern adult volunteers aged 18-50. The first-in-human trial is now being conducted in Oxford in UK healthy adult volunteers. The vaccine will be administered intramuscularly.

Volunteers will be recruited and vaccinated at the King Abdulaziz Medical City, M-NGHA, Riyadh. There will be 3 study groups and a total of 24 volunteers will be enrolled. Staggered enrolment will apply for the first three volunteers within each group. Volunteers will be first recruited into Group 1 and subsequently into Groups 2 and 3 following interim clinical safety reviews. Volunteers will be allocated to a study group by selecting eligible volunteers for enrolment in the order in which they were deemed eligible, following screening.

Conditions
Conditions: Middle East Respiratory Syndrome Coronavirus
Keywords: MERS-CoV
ChAdOx1 MERS
Study Design
Study Type: Interventional
Primary Purpose: Prevention
Study Phase: Phase 1
Interventional Study Model: Parallel Assignment
Open-labelled, non-randomised, dose escalation, extension for a first-in-human, single centre, phase Ib clinical trial
Number of Arms: 3
Masking: None (Open Label)
Allocation: Non-Randomized
Enrollment: 24 [Anticipated]
Arms and Interventions
Arms Assigned Interventions
Experimental: Group 1 (n=6)
will be administered ChAdOx1 MERS: 5 x 109 vp ChAdOx1 MERS
Biological: ChAdOx1 MERS
a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
Experimental: Group 2 (n=9)
will be administered ChAdOx1 MERS: 2.5 x 1010 vp ChAdOx1 MERS
Biological: ChAdOx1 MERS
a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
Experimental: Group 3 (n=9)
will be administered ChAdOx1 MERS: 5 x 1010 vp ChAdOx1 MERS
Biological: ChAdOx1 MERS
a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
Outcome Measures
Primary Outcome Measures:
1. Occurrence of solicited and unsolicited local and systemic adverse events
The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events. Change from baseline for safety laboratory measures will also be collected. Occurrence of serious adverse events will be collected during the whole study duration

[Time Frame: 28 days following the vaccination]
Secondary Outcome Measures:
2. Measures of immunogenicity to the ChAdOx1 MERS vaccine
ELISA to quantify antibodies to MERS Spike protein antigen Ex vivo ELISpot responses to MERS Spike protein antigen

[Time Frame: 6.5 months following completion of the vaccination regimen]
Eligibility
Minimum Age: 18 Years
Maximum Age: 50 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: Yes
Criteria:

Inclusion Criteria:

  1. Healthy* ME adults aged 18 to 50 years
  2. Able and willing (in the Investigator's opinion) to comply with all study requirements
  3. Willing to allow the investigators to access the volunteer's medical history.
  4. For females only, not planning to get pregnant during the study and a negative pregnancy test on the day(s) of screening and vaccination. Effective methods of contraception must be used. See section 6.3.3
  5. Agreement to refrain from blood donation during the course of the study
  6. Provide written informed consent

Exclusion Criteria:

  1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
  2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data.
  3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
  5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  6. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
  7. Any history of anaphylaxis in relation to vaccination
  8. Pregnancy, lactation or willingness/intention to become pregnant during the study
  9. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
  10. History of serious psychiatric condition likely to affect participation in the study
  11. Bleeding disorder (eg. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
  12. Any other serious chronic illness requiring hospital specialist supervision
  13. Suspected or known current alcohol use.
  14. Suspected or known drug abuse in the 5 years preceding enrolment
  15. Seropositive for hepatitis B surface antigen (HBsAg)
  16. Seropositive for hepatitis C virus (antibodies to HCV)
  17. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
  18. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
  19. History of exposure to MERS-CoV *
  20. History of contact with camels. Defined as working in farms or barns; having been within 6 feet (2 meters) of a sick camel without PPE; or consumption of raw milk or uncooked meat. For this study, 30 days prior to screening will be considered.
  21. History of allergic reaction to Aminoglycoside antibiotics. *rRT-PCR testing of nasopharyngeal specimen , at the discretion of PI, may be indicated when a volunteer is suspected to be asymptomatic carrier.
Contacts/Locations
Central Contact: Majed Al Jeraisy, M.Sc.
Telephone: 0096611 849 4455 Ext. 94455
Email: JeraisyM@NGHA.MED.SA
Central Contact Backup: ADEL MUTAIRI, PHD
Telephone: 0096611 849 4455 Ext. 94366
Email: almutairiad1@NGHA.MED.SA
Study Officials: Mohammad Bosaeed, MD
Principal Investigator
Ministry of National Guard-Health Affairs (MNGHA)
Locations:
IPDSharing
Plan to Share IPD: No
References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services